Impact of peritoneal metastasis on overall survival in patients with advanced endometrial cancer receiving lenvatinib plus pembrolizumab.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
33 patients with advanced or recurrent endometrial cancer treated with the LP regimen at Kansai Medical University Hospital between February 2022 and August 2025.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
These findings should be considered hypothesis-generating and warrant prospective validation, particularly for patients with peritoneal metastasis. [SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1007/s12672-026-04843-2.
[PURPOSE] The combination of lenvatinib plus pembrolizumab (LP) is a standard treatment for advanced or recurrent endometrial cancer.
- p-value p = 0.003
- 95% CI 1.84–18.43
- 추적기간 27.6 months
APA
Boku S, Kita M, et al. (2026). Impact of peritoneal metastasis on overall survival in patients with advanced endometrial cancer receiving lenvatinib plus pembrolizumab.. Discover oncology, 17(1). https://doi.org/10.1007/s12672-026-04843-2
MLA
Boku S, et al.. "Impact of peritoneal metastasis on overall survival in patients with advanced endometrial cancer receiving lenvatinib plus pembrolizumab.." Discover oncology, vol. 17, no. 1, 2026.
PMID
41832914 ↗
Abstract 한글 요약
[PURPOSE] The combination of lenvatinib plus pembrolizumab (LP) is a standard treatment for advanced or recurrent endometrial cancer. However, the optimal starting dose of lenvatinib is debated due to its toxicity profile. This study aimed to evaluate the effectiveness and safety of the LP regimen in a real-world setting and to investigate the impact of the lenvatinib starting dose on survival outcomes.
[METHODS] We conducted a retrospective analysis of 33 patients with advanced or recurrent endometrial cancer treated with the LP regimen at Kansai Medical University Hospital between February 2022 and August 2025. We evaluated the objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Prognostic factors for survival were identified using the Kaplan-Meier method and Cox proportional hazards models.
[RESULTS] The median follow-up was 27.6 months. The ORR was 48.5%, with a median PFS of 6.7 months and a median OS of 21.7 months. In exploratory multivariable analysis , a lenvatinib starting dose < 20 mg (vs. 20 mg) was associated with shorter PFS (aHR 5.83; 95% CI 1.84–18.43; p = 0.003). In contrast, peritoneal metastasis (present vs. absent) was independently associated with shorter OS (aHR 7.51; 95% CI 1.87–30.25; = 0.005).
[CONCLUSION] In this real-world cohort, LP therapy was effective and tolerable. In exploratory analyses, lenvatinib starting dose and peritoneal metastasis showed distinct associations with PFS and OS, respectively; however, non-random dose selection and baseline imbalances limit causal interpretation. These findings should be considered hypothesis-generating and warrant prospective validation, particularly for patients with peritoneal metastasis.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1007/s12672-026-04843-2.
[METHODS] We conducted a retrospective analysis of 33 patients with advanced or recurrent endometrial cancer treated with the LP regimen at Kansai Medical University Hospital between February 2022 and August 2025. We evaluated the objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Prognostic factors for survival were identified using the Kaplan-Meier method and Cox proportional hazards models.
[RESULTS] The median follow-up was 27.6 months. The ORR was 48.5%, with a median PFS of 6.7 months and a median OS of 21.7 months. In exploratory multivariable analysis , a lenvatinib starting dose < 20 mg (vs. 20 mg) was associated with shorter PFS (aHR 5.83; 95% CI 1.84–18.43; p = 0.003). In contrast, peritoneal metastasis (present vs. absent) was independently associated with shorter OS (aHR 7.51; 95% CI 1.87–30.25; = 0.005).
[CONCLUSION] In this real-world cohort, LP therapy was effective and tolerable. In exploratory analyses, lenvatinib starting dose and peritoneal metastasis showed distinct associations with PFS and OS, respectively; however, non-random dose selection and baseline imbalances limit causal interpretation. These findings should be considered hypothesis-generating and warrant prospective validation, particularly for patients with peritoneal metastasis.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1007/s12672-026-04843-2.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (2)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Environmental endocrine disruptors and endometrial cancer: a systematic review of epidemiological studies.
- Association of immune-related adverse events with survival in patients receiving immune checkpoint inhibitor plus chemotherapy for lung cancer.
- Cost-effectiveness of pembrolizumab plus chemotherapy for metastatic non-small cell lung cancer: a head-to-head trial vs. real-world comparison.
- Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study.
- Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab.
- Phase II randomized study of first-line carboplatin and paclitaxel in combination with pembrolizumab, followed by maintenance pembrolizumab alone or with nesuparib, in mismatch-repair proficient, advanced or recurrent endometrial cancer (PENELOPE).